Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Daiichi Sankyo
Express Scripts
Teva
Deloitte
Covington

Generated: March 24, 2019

DrugPatentWatch Database Preview

SUSTIVA Drug Profile

« Back to Dashboard

When do Sustiva patents expire, and what generic alternatives are available?

Sustiva is a drug marketed by Bristol Myers Squibb and is included in two NDAs. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has seventy-seven patent family members in twenty-eight countries.

The generic ingredient in SUSTIVA is efavirenz. There are twenty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the efavirenz profile page.

Drug patent expirations by year for SUSTIVA
Synonyms for SUSTIVA
(-)-6-CHLORO-4-CYCLOPROPYLETHYNYL-4-TRIFLUOROMETHYL-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONE
(4S)-6-chloranyl-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-(cyclopropyl-ethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazine-2-one
(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-ben zoxazin-2-one
(S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
(S)-6-CHLORO-4-(CYCLOPROPYLETHYNYL)-4-(TRIFLUOROMETHYL)-1H-BENZO[D][1,3]OXAZIN-2(4H)-ONE
(s)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-Efavirenz
154598-52-4
1ikv
1ikw
2H-3, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-
2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)-
598E524
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
A809555
AB00639956-06
AB00639956-08
AB21723
AC-25006
AC1L20IX
ACM154801748
AKOS015894951
AOB2950
API0002525
BC214923
BCP27719
BCP9000636
BCPP000245
BDBM2483
BIDD:GT0383
C-19450
C08088
C14H9ClF3NO2
CAS-154598-52-4
CC-27439
CCG-101011
CHEBI:119486
CHEMBL223228
CJ-31514
CPD000466351
CS-2154
CTK8E9137
D00896
DB00625
DL-535
DMP 266
DMP-266
DMP-266; Efavirenz
DSSTox_CID_26029
DSSTox_GSID_46029
DSSTox_RID_81298
DTXSID9046029
E0997
efavirenz
Efavirenz (JAN/INN)
Efavirenz [USP:INN:BAN]
Efavirenz & IFNL1
Efavirenz & IFNL2
Efavirenz & IFNL3
Efavirenz & IL-28A
Efavirenz & IL-28B
Efavirenz & IL-29
Efavirenz & Interferon lambda-1
Efavirenz & Interferon lambda-2
Efavirenz & Interferon lambda-3
Efavirenz & Interleukin 28A
Efavirenz & Interleukin 28B
Efavirenz & Interleukin 29
Efavirenz & PLGA
Efavirenz & Poly-lactide-co-glycolide
Efavirenz solution, 1.0 mg/mL in acetonitrile, certified reference material
Efavirenz, (S)
efavirenz, (S)-isomer
Efavirenz, >=98% (HPLC)
Efavirenz, United States Pharmacopeia (USP) Reference Standard
Efavirenzum
EFV
EFV & IFNL1
EFV & IFNL2
EFV & IFNL3
EFV & IL-28A
EFV & IL-28B
EFV & IL-29
EFV & Interferon lambda-1
EFV & Interferon lambda-2
EFV & Interferon lambda-3
EFV & Interleukin 28A
EFV & Interleukin 28B
EFV & Interleukin 29
EFV & PLGA
EFZ
Eravirenz
FT-0625647
GP6354
HMS2051J08
HMS2090N16
HMS3393J08
HMS3713M14
HSDB 7163
HY-10572
J-520431
JE6H2O27P8
KB-50519
KS-00000ZEH
KS-00002WWM
KS-5380
L 743726
L-743,726
L-743725
L-743726
LS-173464
Met-SDF-1.beta. & Efavirenz
Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz
MFCD05662344
MLS000759465
MLS001424087
MolPort-003-983-924
NC00261
NCGC00159337-02
NCGC00159337-04
NCGC00271713-05
NSC-742403
NSC742403
PubChem5812
RL01986
RTX-012332
s4685
SAM001246667
SC-46515
SCHEMBL37762
SMR000466351
SR-01000759360
SR-01000759360-4
SR-01000759360-5
Stocrin
Strocin (TM)
Sustiva (TM)
Sustiva (TN)
Tox21_111582
Tox21_111582_1
UNII-JE6H2O27P8
XPOQHMRABVBWPR-ZDUSSCGKSA-N
Z2186909878
ZINC2020233

US Patents and Regulatory Information for SUSTIVA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-001 Sep 17, 1998 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-002 Sep 17, 1998 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-001 Sep 17, 1998 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for SUSTIVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-003 Sep 17, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-002 Sep 17, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb SUSTIVA efavirenz TABLET;ORAL 021360-002 Feb 1, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for SUSTIVA
Drugname Dosage Strength RLD Date
➤ Subscribe Capsules 50 mg, 100 mg and 200 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Tablets 600 mg ➤ Subscribe ➤ Try a Free Trial

Supplementary Protection Certificates for SUSTIVA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0582455 C300032 Netherlands ➤ Try a Free Trial PRODUCT NAME: EFAVIRENZ; REGISTRATION NO/DATE: EU/1/99/110/001-004, EU/1/99/111/001-004 19990528
0582455 SPC/GB00/035 United Kingdom ➤ Try a Free Trial PRODUCT NAME: EFAVIRENZ, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: CH IKS-54 908 01 19981120; CH IKS-54 908 02 19981120; CH IKS-54 908 03 19981120; UK EU/1/99/110/001 19990528; UK EU/1/99/110/002 19990528; UK EU/1/99/110/003 19990528; UK EU/1/99/110/004 19990528; UK EU/1/99/111/001 19990528; UK EU/1/99/111/002 19990528; UK EU/1/99/111/003 19990528; UK EU/1/99/111/004 19990528
0915894 C00915894/02 Switzerland ➤ Try a Free Trial PRODUCT NAME: TENOFOVIRDISOPROXIL + EFAVIRENZ + EMTRICITABIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 60011 20.11.2009
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
UBS
Mallinckrodt
Argus Health
Chubb
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.